Diagnosis and Treatment of Inflammatory Cerebral Amyloid Angiopathy
Purpose of review In this article, we discuss the current consensus approach to the evaluation and treatment of inflammatory cerebral amyloid angiopathy (CAA). We also outline critical knowledge gaps and identify questions for future research. Recent findings Recent cohort studies found that immunosuppressive treatment for inflammatory CAA was associated with higher probability of clinical and radiographic improvement and reduced risk of disease recurrence. A recent case series showed correlations between changes in cerebrospinal fluid levels of anti-Aβ autoantibodies, changes in microglial activation, and clinical and radiographic response to immunosuppressive treatment; these data provide supporting evidence for a pathophysiological link between inflammatory CAA and adverse events associated with Alzheimer’s disease (AD) immunotherapy treatments. Summary Despite many knowledge gaps, widely accepted methods for diagnosis and management of inflammatory CAA have emerged, including validated clinical and radiographic criteria and treatment with immunosuppressive medications. Still, there is considerable space for diagnosis and treatment paradigms to advance in tandem with our understanding of the disease. Efforts to optimize protocols for clinical and radiographic assessment, identify biomarkers at multiple stages of disease, and leverage insights from Alzheimer’s disease biomarkers and therapeutics will be pivotal to achieving these goals..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current treatment options in neurology - 25(2023), 7 vom: 18. Mai, Seite 187-197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bruce, Samuel S. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
ABRA |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11940-023-00755-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144195897 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144195897 | ||
| 003 | DE-627 | ||
| 005 | 20240118093729.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11940-023-00755-6 |2 doi | |
| 035 | |a (DE-627)OLC2144195897 | ||
| 035 | |a (DE-He213)s11940-023-00755-6-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Bruce, Samuel S. |e verfasserin |0 (orcid)0000-0002-4502-1572 |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and Treatment of Inflammatory Cerebral Amyloid Angiopathy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of review In this article, we discuss the current consensus approach to the evaluation and treatment of inflammatory cerebral amyloid angiopathy (CAA). We also outline critical knowledge gaps and identify questions for future research. Recent findings Recent cohort studies found that immunosuppressive treatment for inflammatory CAA was associated with higher probability of clinical and radiographic improvement and reduced risk of disease recurrence. A recent case series showed correlations between changes in cerebrospinal fluid levels of anti-Aβ autoantibodies, changes in microglial activation, and clinical and radiographic response to immunosuppressive treatment; these data provide supporting evidence for a pathophysiological link between inflammatory CAA and adverse events associated with Alzheimer’s disease (AD) immunotherapy treatments. Summary Despite many knowledge gaps, widely accepted methods for diagnosis and management of inflammatory CAA have emerged, including validated clinical and radiographic criteria and treatment with immunosuppressive medications. Still, there is considerable space for diagnosis and treatment paradigms to advance in tandem with our understanding of the disease. Efforts to optimize protocols for clinical and radiographic assessment, identify biomarkers at multiple stages of disease, and leverage insights from Alzheimer’s disease biomarkers and therapeutics will be pivotal to achieving these goals. | ||
| 650 | 4 | |a Cerebral amyloid angiopathy | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a ABRA | |
| 650 | 4 | |a CAA-ri | |
| 700 | 1 | |a Parikh, Neal S. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in neurology |d Springer US, 1999 |g 25(2023), 7 vom: 18. Mai, Seite 187-197 |w (DE-627)334292751 |w (DE-600)2057342-X |x 1092-8480 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:7 |g day:18 |g month:05 |g pages:187-197 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11940-023-00755-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 7 |b 18 |c 05 |h 187-197 | ||